Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates
Published November 17, 2025 Novo Nordisk moved aggressively today to cut out‑of‑pocket costs for its blockbuster GLP‑1 drugs Wegovy and Ozempic, unveiling new self‑pay prices and limited‑time offers that it says will reach tens of thousands of U.S. pharmacies and telehealth partners. The changes come just days after the Trump administration struck landmark pricing agreements with Novo Nordisk and Eli Lilly that will extend Medicare and Medicaid coverage to obesity drugs for the first time and launch a government-run discount pharmacy site, TrumpRx, in early 2026. The White House+2Reuters+2 At the same time, telehealth and discount platforms including GoodRx and